EcoDrugPlus

Atrial Natriuretic Peptide Receptor 1-Like

Ensembl ID : ENSCGOG00000004003
Gene Symbol: LOC115004646
2 Cross references
193 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 1-Like

Ensembl ID : ENSCGOG00000015661
Gene Symbol: LOC115020956
2 Cross references
191 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 2-Like

Ensembl ID : ENSCGOG00000008025
Gene Symbol: LOC115016547
2 Cross references
186 Possible Orthologues:

Aurora Kinase A

Ensembl ID : ENSCGOG00000013220
Gene Symbol: AURKA
3 Cross references
233 Possible Orthologues:

Aurora Kinase B-Like

Ensembl ID : ENSCGOG00000011322
Gene Symbol: LOC115014826
3 Cross references
205 Possible Orthologues:

Beta-1 Adrenergic Receptor-Like

Ensembl ID : ENSCGOG00000023294
Gene Symbol: LOC115013959
3 Cross references
197 Possible Orthologues:

Beta-2 Adrenergic Receptor-Like

Ensembl ID : ENSCGOG00000015521
Gene Symbol: LOC115014918
3 Cross references
196 Possible Orthologues:

Beta-Secretase 1

Ensembl ID : ENSCGOG00000009854
Gene Symbol: BACE1
3 Cross references
221 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSCGOG00000004337
Gene Symbol: BDKRB2
3 Cross references
160 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSCGOG00000006376
Gene Symbol: BDKRB2
3 Cross references
242 Possible Orthologues:

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSCGOG00000015636
Gene Symbol: LOC115014038
3 Cross references
203 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4b-Like

Ensembl ID : ENSCGOG00000016907
Gene Symbol: LOC115022201
2 Cross references
224 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).